About Penta
Who we are
Diversity and Inclusion
Penta ID Network
Penta Foundation Italy
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Call for services
Brighter Future Award
Archivio
Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial
Inadequate hospital practices to prevent mother-to-child transmission of Hepatitis B Virus infection: A European survey
SMILE once-daily regimen non-inferior to triple ART regimen
COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa
Inaugural training session for UNIVERSAL’s Clinical Trial Management course
Penta signs the 2022 Rome Action plan to intensify commitment to scaling up prevention, diagnosis and treatment of paediatric HIV and TB
Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies
🇬🇧 Penta unveils Brighter Future Award 2023: Recognising innovators and visionaries driving positive change
Nominations are open for the Penta Brighter Future Award!
Lessons learned from the HIV pandemic to strengthen qualitative research methods for (re)emerging infections
Join the webinar “Facilitating clinical evaluation of novel products for children” on 14 June
Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)
Global study highlights deaths from neonatal sepsis and steps to improve treatment
🇮🇹 Sepsi nei neonati: ancora alta la mortalità nel mondo. Nuovi strumenti per facilitare diagnosi e cura
🇬🇧 Global study highlights deaths from neonatal sepsis and steps to improve treatment
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial